Novavax stock up 4.4% premarket after it says 1 million COVID vaccine doses now available in the U.K.

Novavax Inc. said Tuesday that one million doses of its protein-based COVID vaccine Nuvaxovid are now available in the U.K. “With U.K. data showing that people infected with both COVID-19 and the flu are more than five times as likely to die compared to someone with no infection(1) , it is more important than ever to consider any vaccine offered to you by the National Health Service,” said Stanley C. Erck, Novavax chief executive, in a statement. The Novavax vaccine uses more conventional technology than the mRNA-based ones developed by Pfizer , BioNTech and Moderna , that were first to be approved and used widely in the pandemic. Shares were up 4.4% premarket but have fallen 87% in the year to date, while the S&P 500 has fallen 23%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.